Search results

RSS feed for this result

128,825 results

Book
viii, 270 pages : illustrations ; 24 cm
  • Introduction / William C. Olsen and Carolyn Sargent
  • Biomedicine and African healing
  • The value of secrets: pragmatic healers and proprietary knowledge / Stacey Langwick
  • Body and sunsum: stroke in Asante / William C. Olsen
  • Spirits and pills who are against children: medico-rituals and assisted reproductive technologies in a Tuareg couple's quest for parenthood / Susan J. Rasmussen
  • Science in the moral space of health and healing paradigms in western equatorial Africa / John M. Janzen
  • Medical pluralism revisted: a memoir / Brooke Grundfest Schoepf
  • Symptoms and therapeutic pluralities
  • Wishful doing: journeying in a Nigerian medical landscape / Ulrika Trovalla
  • The individualization of illness: bewitchment and the mental in postcolonial Tanzania / Koen Stroeken
  • Ihahamuka-PTSD in postgenocidal Rwanda: culture, continuity and change in Rwandan therapeutics / Christopher C. Taylor
  • Hospital ethnography
  • Ear infections, malnutrition, and circuitous health care treatments in Zaria, Nigeria / Elisha Renne
  • Therapeutic eclecticism and cancer care in a Kenyan hospital ward / Benson A. Mulemi
  • Elusive paths, fluid care: seeking healing and protection in the Republic of Benin / Carolyn Sargent and James Leslie Kennell
  • Legitimate care, dangerous care, and childbirth in an urban African community / Claire Wendland
  • Afterword / Arthur Kleinman.
In most places on the African continent, multiple health care options exist and patients draw on a therapeutic continuum that ranges from traditional medicine and religious healing to the latest in biomedical technology. The ethnographically based essays in this volume highlight African ways of perceiving sickness, making sense of and treating suffering, and thinking about health care to reveal the range and practice of everyday medicine in Africa through historical, political, and economic contexts.
(source: Nielsen Book Data)9780253024916 20170410
SAL1&2 (on-campus shelving)
Book
1 online resource (x, 226 pages) : illustrations.
  • 1. Alcohol a double-edged sword: Health benefits with moderate consumption but a health hazard with excess alcohol intake 2. Drugs of abuse: An overview 3. Designer drugs including bath salts and spices 4. Combined alcohol and drug abuse: A potentially deadly mix 5. Link between environmental factors, personality factors, and addiction 6. Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse 7. Pharmacogenomics of abused drugs 8. Association between polymorphisms in genes encoding various receptors, transporters, and enzymes and alcohol/drug addiction 9. Methods of alcohol measurement 10. Laboratory methods for measuring drugs of abuse in urine 11. Analysis of drugs of abuse in serum, hair, oral fluid, sweat, and meconium.
  • (source: Nielsen Book Data)9780128054550 20170313
Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials.
(source: Nielsen Book Data)9780128054550 20170313
Book
171 pages ; 22 cm.
  • L'hôtel-Dieu -- L'huile de petits chiens -- Le balafré -- La ligature des vaisseaux -- Prisonnier -- Le tournoi fatal -- Le grand tour -- La polémique -- La peste -- La Saint-Barthélemy -- Epilogue -- Bibliographie.
"Né vers 1510 et mort en 1590, Ambroise Paré a traversé la quasi-totalité de ce XVIe siècle, haut en couleur et en furie, agité par les guerres extérieures entre le royaume de France et le Saint-Empire romain germanique, comme à l'intérieur par les guerres de religion. Simple barbier ne sachant pas le latin, devenu chirurgien du roi par le seul privilège de sa compétence, il a servi dans les armées de François 1er, de son fils Henri II, puis successivement des trois fils que celui-ci avait eus de Catherine de Médicis, François II, Charles IX et Henri III et il leur a survécu. Chirurgien de guerre, il a participé aux grandes batailles et aux sièges qui ont émaillé ce siècle. Il a senti le vent du boulet, il a vécu les horreurs de la guerre, il a franchi les lignes ennemies et il a été fait prisonnier. Il a opéré des milliers de soldats et de capitaines, des grands du royaume de France et d'ailleurs, et les rois eux-mêmes. Il a survécu à une morsure de vipère, à la peste, à la jalousie et au poison, comme au massacre de la Saint-Barthélemy. Ce livre relate les épisodes les plus épiques de sa vie aventureuse dans leur contexte historique."--Page 4 of cover.
SAL1&2 (on-campus shelving)
Book
230 pages : illustrations ; 23 cm
SAL1&2 (on-campus shelving)
Book
1 online resource (102 pages)
  • Front Cover ; Analysis for Time-to-Event Data under Censoring and Truncation; Copyright; Contents; Chapter 1 Introduction ; 1.1 Introduction to the book; 1.2 Examples; 1.3 Brief review of survival analysis under truncation; 1.4 Preliminaries; Chapter 2 Survival analysis for univariate truncated data ; 2.1 Introduction; 2.2 Nonparametric estimation; 2.3 Linear Rank Statistics for umbrella alternative hypothesis; 2.4 Regression analysis for truncated and censored data; Chapter 3 Bivariate estimation with truncated survival data ; 3.1 Introduction; 3.2 Bivariate distributions.
  • 3.3 Types of bivariate truncated survival data3.4 The inverse probability weighted estimator with only one censoring variable; 3.5 The transformation estimator; 3.6 Example; 3.7 Discussion; Chapter 4 Accelerated failure time model for truncated and censored survival data ; 4.1 Introduction; 4.2 WLS estimator for univariate LTRC data under AFT model ; 4.3 AFT model for bivariate survival data under truncation and censoring; Chapter 5 Recent advances for truncated survival data ; 5.1 Linear transformation models; 5.2 Joint modelling of survival events and longitudinal data under random truncationBibliography; Index; Back Cover.
Book
1 online resource (xxi, 570 pages) : illustrations.
  • Anti-Aging Drugs: Where are We and Where are We Going? / Alexander M. Vaiserman and Oleh V. Lushchak
  • Aging: Natural or Disease? A View from Medical Textbooks / S. Janac, B. Clarke and D. Gems
  • The Search for the "Anti-Aging Pill": A Critical Viewpoint / Éric le Bourg
  • Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons / Alexander N. Khokhlov and Galina V. Morgunova
  • Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development / Ramón Cacabelos, Juan Carlos Carril and Oscar Teijido
  • Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications / Anila Mathew, Francesco Marotta and D. Sakthi Kumar
  • Hormetins as Drugs for Healthy Aging / Suresh I. S. Rattan
  • Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability / V. K. Koltover
  • Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs / Elena G. Pasyukova, Boris A. Feniouk and Vladimir P. Skulachev
  • Mimetics of Caloric Restriction / Oleh Lushchak and Dmytro Gospodaryov
  • Allosteric SIRT1 Activators as Putative Anti-Aging Drugs / Basil P. Hubbard
  • Therapeutic Potential of Sirtuin Inhibitors in Cancer / Francisco Javier Alcain, Consuelo M. Nieva, Lucía Fernández del Río, Raquel Santiago-Mora, Elena Gutiérrez-Casado, Mario Duran-Prado and Jose M. Villalba
  • Lifespan-Extending Effect of Resveratrol and Other Phytochemicals / Shin-Hae Lee and Kyung-Jin Min
  • Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR) / Dudley W. Lamming
  • mTOR, Aging and Cancer: Prospects for Pharmacological Interventions / Z. D. Sharp
  • Anti-Aging Action of PPARs: Potential Therapeutic Targets / Ki Wung Chung, Byung Pal Yu and Hae Young Chung
  • Antidiabetic Biguanides as Anti-Aging Drugs / Vladimir N. Anisimov
  • S-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine? / W. A. M. Loenen
  • Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan / R. Hardeland
  • Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span / Vladimir Khavinson and Irina Popovich
  • HDAC Inhibitors: A New Avenue in Anti-Aging Medicine / E. G. Pasyukova and A. M. Vaiserman
  • Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy / Ilia Stambler.
Provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.
Book
1 online resource.
  • List of Contributors xvii Preface xxi Historical Perspective: What Makes Antibody Drug Conjugates Revolutionary? xxiii Part I What is an Antibody Drug Conjugate 1 1 Typical Antibody Drug Conjugates 3 John M. Lambert 1.1 Introduction 3 1.2 The Building Blocks of a Typical ADC 6 1.3 Building an ADC Molecule 13 1.4 Attributes of a Typical ADC 19 1.5 Summary 24 Acknowledgment 24 Abbreviations 25 References 25 Part II Engineering, Manufacturing, and Optimizing Antibody Drug Conjugates 33 2 Selecting Optimal Antibody Drug Conjugate Targets Using Indication-Dependent or Indication-Independent Approaches 35 Jay Harper and Robert Hollingsworth 2.1 Characteristics of an Optimal ADC Target 35 2.2 Indication-Dependent ADC Target Selection 40 2.3 Indication-Independent ADC Target Selection 48 2.4 Concluding Remarks and Future Directions 50 Acknowledgments 52 References 52 3 Antibody Drug Conjugates: An Overview of the CMC and Characterization Process 59 Philip L. Ross and Janet Wolfe 3.1 Introduction 59 3.2 ADC Manufacturing Process 60 3.3 Characterization 70 3.4 Comparability 76 3.5 Concluding Remarks 76 Abbreviations 77 References 78 4 Linker and Conjugation Technology-- and Improvements 85 Riley Ennis and Sourav Sinha 4.1 Overview 85 4.2 Noncleavable 86 4.3 Cleavable Linkers and Self -Immolative Groups 86 4.4 Differences in Therapeutic Window of Cleavable and Noncleavable Linkers 88 4.5 Improving Therapeutic Window with Next -Generation Linker Technologies 89 4.6 Site -Specific Conjugation, Homogeneous Drug Species, and Therapeutic Window 91 4.7 Influence of Linkers on Pharmacokinetics and ADME 93 4.8 PEG Linkers to Optimize Clearance, Solubility, and Potency 93 4.9 Linkers to Optimize for Drug Resistance 94 4.10 Improving Solid Tumor Penetration with Linkers 96 4.11 Analytical Methods for Characterizing Linker Pharmacodynamics 96 4.12 Conclusion 98 References 99 5 Formulation and Stability 105 Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake 5.1 Introduction 105 5.2 Stability Considerations for ADCs 106 5.3 Formulation Approaches 115 5.4 Logistical Considerations 123 5.5 Summary and Close 125 References 126 6 QC Assay Development 131 Xiao Hong. Chen and Mate Tolnay 6.1 Introduction 131 6.2 Drug -to -Antibody Ratio 132 6.3 Drug Loading Distribution 133 6.4 Positional Isomers 136 6.5 ADC Concentration 136 6.6 Drug -Related Substances 137 6.7 Antigen Binding Assays and Potential Impact of Drug Conjugation 137 6.8 Cell -Based Cytotoxicity Assays 139 6.9 Assays to Monitor Fc -Dependent Effector Functions to Characterize Additional Possible Mechanisms of Action 140 6.10 Immunogenicity Assays to Monitor the Immune Response to ADC 142 6.11 Conclusions 144 6.12 Key Guidance Documents 145 Acknowledgments 145 References 145 7 Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads 151 Robert Sussman and John Farris 7.1 Introduction 151 7.2 Background on ADCs 152 7.3 Occupational Hazard Assessment of ADCs and Their Components 157 7.4 Occupational Implications and Uncertainties 159 7.5 General Guidance for Material Handling 160 7.6 Facility Features and Engineering Controls 163 7.7 Specific Operational Guidance 165 7.8 Personal Protective Equipment 167 7.9 Training 168 7.10 Industrial Hygiene Monitoring 169 7.11 Medical Surveillance Program 171 7.12 Summary and Future Direction 172 References 172 Part III Nonclinical Approaches 177 8 Bioanalytical Strategies Enabling Successful ADC Translation 179 Xiaogang Han, Steven Hansel, and Lindsay King 8.1 Introduction 179 8.2 ADC LC/MS Bioanalytical Strategies 182 8.3 Non -Regulated ADC Pharmacokinetic and Immunogenicity Support Using Ligand Binding Assays 190 8.4 Biodistribution Assessment 195 8.5 Regulated ADC Pharmacokinetics and Immunogenicity Evaluation 196 8.6 ADC Biomeasures and Biomarkers 199 8.7 Summary 200 References 201 9 Nonclinical Pharmacology and Mechanistic Modeling of Antibody Drug Conjugates in Support of Human Clinical Trials 207 Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta 9.1 Introduction 207 9.2 Cell Line Testing 210 9.3 Xenograft Models 214 9.4 Nonclinical Testing to Support Investigational New Drug Applications 216 9.5 Mechanistic Modeling of Antibody Drug Conjugates 220 9.6 Target -Mediated Toxicity of Antibody Drug Conjugates 228 9.7 Considerations for Nonclinical Testing Beyond Antibody Drug Conjugate Monotherapies 229 9.8 Summary 230 Acknowledgments 231 References 231 10 Pharmacokinetics of Antibody Drug Conjugates 245 Amrita V. Kamath 10.1 Introduction 245 10.2 Pharmacokinetic Characteristics of an ADC 246 10.3 Unique Considerations for ADC Pharmacokinetics 250 10.4 Tools to Characterize ADC PK/ADME 254 10.5 Utilization of ADC Pharmacokinetics to Optimize Design 257 10.6 Pharmacokinetics of Selected ADCs 259 10.7 Summary 261 References 262 11 Path to Market Approval: Regulatory Perspective of ADC Nonclinical Safety Assessments 267 M. Stacey Ricci, R. Angelo De Claro, and Natalie E. Simpson 11.1 Introduction 267 11.2 FDA Experience with ADCs 268 11.3 Regulatory Perspective of the Nonclinical Safety Assessment of ADCs 269 11.4 Concluding Remarks 282 References 283 Part IV Clinical Development and Current Status of Antibody Drug Conjugates 285 12 Antibody Drug Conjugates: Clinical Strategies and Applications 287 Heather E. Vezina, Lucy Lee, Brian J. Schmidt, and Manish Gupta 12.1 Antibody Drug Conjugates in Clinical Development 287 12.2 Therapeutic Indications 291 12.3 Transitioning from Discovery to Early Clinical Development 292 12.4 Challenges and Considerations in the Design of Phase 1 Studies 293 12.5 First-in-Human Starting Dose Estimation 293 12.6 Dosing Strategy Considerations 294 12.7 Dosing Regimen Optimization 295 12.8 Phase 1 Study Design 297 12.9 Supportive Strategies for Phase 1 and Beyond 299 12.10 Clinical Pharmacology Considerations 301 12.11 Organ Impairment Assessments 301 12.12 Drug Drug Interaction Assessments 302 12.13 Immunogenicity 303 12.14 QT/QTc Assessments 303 12.15 Pharmacometric Strategies 307 12.16 Using Physiologically Based Pharmacokinetic and Quantitative Systems Pharmacology Models with Clinical Data 308 12.17 Summary and Conclusions 311 Acknowledgments 311 References 311 13 Antibody Drug Conjugates (ADCs) in Clinical Development 321 Joseph McLaughlin and Patricia LoRusso 13.1 Introduction and Rationale 321 13.2 Components of ADCs in Development 321 13.3 Landscape of ADCs 329 13.4 Clinical Use of ADCs 330 13.5 Future of ADCs 330 13.6 ADCs in Development 330 13.7 Future Directions 340 References 340 14 ADCs Approved for Use: Trastuzumab Emtansine (Kadcyla(R), T-DM1) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer 345 Gail D. Lewis Phillips, Sanne de Haas, Sandhya Girish, and Ellie Guardino 14.1 Introduction 345 14.2 Preclinical Development of T-DM1 348 14.3 Early Clinical Studies of T-DM1 357 14.4 Clinical Pharmacology and Pharmacokinetics 361 14.5 Phase III Studies of T-DM1 in Patients with HER2-Positive MBC 362 14.6 Future Directions 371 14.7 Summary 373 References 374 15 ADCs Approved for Use: Brentuximab Vedotin 381 Monica Mead and Sven de Vos 15.1 Introduction 381 15.2 Early Efforts to Target CD30 with Monoclonal Antibodies 383 15.3 BV: Preclinical Data 386 15.4 Clinical Context 394 15.5 Mechanisms of Resistance 395 15.6 Current Research 397 15.7 Discussion 400 References 401 16 Radioimmunotherapy 409 Savita V. Dandapani and Jeffrey Wong 16.1 History of Radioimmunotherapy 409 16.2 Radioisotopes 410 16.3 Chemistry of RIT 411 16.4 Radioimmunotherapy Antibody Targets in Use Today (Table 16.2) 412 16.5. Other Hematologic Targets 415 16.6 Solid Tumors 417 16.7 Combination Therapy with RIT: Chemotherapy and/or Radiation 420 16.8 RIT and External Beam Radiation Treatment (EBRT) 421 16.9 RIT and EBRT and Chemotherapy 421 16.10 RIT Administration 422 16.11 Future of RIT 422 References 423 Part V Future Perspectives in Antibody Drug Conjugate Development 431 17 Radiolabeled Antibody -Based Imaging in Clinical Oncology 433 Bart S. Hendriks and Daniel F. Gaddy 17.1 Introduction 433 17.2 Applications for Clinical Antibody Imaging 434 17.3 Antibodies as Imaging Agents 435 17.4 Nuclear Imaging Gamma Camera (Planar) Scintigraphy and SPECT 439 17.5 Nuclear Imaging - PET 448 17.6 Commercialization Considerations 456 17.7 Summary 461 References 462 18 Next-Generation Antibody Drug Conjugate Technologies 473 Amy Q. Han and William C. Olson 18.1 Introduction 473 18.2 Novel Cytotoxic Payloads and Linkers 474 18.3 Tailoring Antibodies for Use as ADCs 482 18.4 Conclusions 491 References 491 Index 505.
  • (source: Nielsen Book Data)9781119060680 20170313
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging Includes case studies of ADCs in oncology drug development Features contributions from highly-regarded experts on the frontlines of ADC research and development.
(source: Nielsen Book Data)9781119060680 20170313
Book
1 online resource (xv, 258 pages).
  • Chapter 1. Introduction Chapter 2. Prevalence of Anxiety in Autism Spectrum Disorders Chapter 3. Phenomenology and Presentation of Anxiety in Autism Spectrum Disorder Chapter 4. Neurobiological Mechanisms of Anxiety in ASD Chapter 5. Assessment of Anxiety in Youth With Autism Spectrum Disorder Chapter 6. Cognitive-Behavioral Principles and Their Applications Within Autism Spectrum Disorder Chapter 7. Individual CBT for Anxiety and Related Symptoms in Children With Autism Spectrum Disorders Chapter 8. Group Cognitive Behavior Therapy for Children and Adolescents With Anxiety and Autism Spectrum Disorders Chapter 9. Behavioral Treatments for Anxiety in Adults With Autism Spectrum Disorder Chapter 10. Behavioral Treatments for Anxiety in Minimally Verbal Children With ASD Chapter 11. Anxiety and ASD in Schools: School-Related Issues and Individualized Education Programs Chapter 12. Dissemination and Implementation of Behavioral Treatments for Anxiety in ASD.
  • (source: Nielsen Book Data)9780128051221 20170313
Anxiety in Children and Adolescents with Autism Spectrum Disorder: Evidence-Based Assessment and Treatment begins with a general overview of the history of research on anxiety in ASD and the path towards evidence-based assessment and treatment methods. Thereafter, chapters focus on the nature of ASD and anxiety comorbidity, the assessment of anxiety in ASD, and its treatment. Later chapters are devoted to future directions for research on this topic, including a discussion of anxiety assessment and treatment for adults and minimally verbal individuals. Anxiety disorders in children with autism spectrum disorder (ASD) can cause substantial distress and impairment over and above that caused by ASD alone. Emerging research on genetic, psychological, psychophysiological, and psychometric aspects of ASD establish anxiety as a valid and necessary treatment target in this population. This book is designed to help a broad array of providers who work with children with ASD understand cutting-edge, empirically supported treatments for anxiety, including specific treatment plans and strategies.
(source: Nielsen Book Data)9780128051221 20170313
Book
2 volumes : illustrations ; 29 cm.
  • Volume 1: Foundations in knowledge
  • Volume 2: Trauma practice.
"The two volume 'APA Handbook of Trauma Psychology' is the most comprehensive guide, text, and reference work on the subject to date. It provides a survey of all the major areas and subtopics of empirical knowledge and practical applications in the field of trauma psychology, written by top experts in the field."--The publisher.
SAL1&2 (on-campus shelving)
Book
1 online resource.
  • Basic Concepts for Statistical Modeling
  • Introduction to Simple Linear Regression Models
  • Matrix Representation of the Linear Regression Model
  • Evaluation of Partial Tests of Hypotheses in a MLRM
  • Selection of Variables in a Multiple Linear Regression Model
  • Correlation Analysis
  • Strategies for Assessing the Adequacy of the Linear Regression Model
  • Weighted Least-Squares Linear Regression
  • Generalized Linear Models
  • Poisson Regression Models for Cohort Studies
  • Logistic Regression in Case-Control Studies
  • Regression Models in a Cross-Sectional Study
  • Solutions to Practice Exercises.
Book
xiii, 290 pages, 32 unnumbered pages of plates : color illustrations, map ; 24 cm.
For more than one thousand years Arab medicine held sway in the ancient world, from the shores of Spain in the West to China, India and Sri Lanka (Ceylon) in the East. This book explores the impact of Greek (as well as Indian and Persian) medical heritage on the evolution of Arab medicine and pharmacology, investigating it from the perspective of materia medica - a reliable indication of the contribution of this medical legacy. Focusing on the main substances introduced and traded by the Arabs in the medieval Mediterranean - including Ambergris, camphor, musk, myrobalan, nutmeg, sandalwood and turmeric - the authors show how they enriched the existing inventory of drugs influenced by Galenic-Arab pharmacology. Further, they look at how these substances merged with the development and distribution of new technologies and industries that evolved in the Middle Ages such as textiles, paper, dyeing and tanning, and with the new trends, demands and fashions regarding spices, perfumes, ornaments (gemstones) and foodstuffs some of which can be found in our modern-day food basket.
(source: Nielsen Book Data)9780748697816 20170313
SAL1&2 (on-campus shelving)
Book
1 online resource : illustrations
  • Chapter 1. Sinus Node - Normal and Abnormal Rhythms Chapter 2. Bradyarrhythmias - Conduction System Abnormalities Chapter 3. Ectopic Complexes and Rhythms Chapter 4. Tachycardia Chapter 5. Supraventricular Tachyarrhythmias Chapter 6. Ventricular Tachyarrhythmias Chapter 7. Cardiac Pacing and Pacemaker Rhythms Chapter 8. Implantable Cardioverter Defibrillators Chapter 9. Drug Effects and Electrolyte Disorders Chapter 10. Athletes and Arrhythmias Chapter 11. Evaluation of the Patient with Suspected Arrhythmias Chapter 12. Treatment of Arrhythmias Chapter 13. Management of Arrhythmias in Pregnancy.
  • (source: Nielsen Book Data)9780323399685 20170410
Concise, compact, fully-illustrated and easy to read, Arrhythmia Essentials, 2nd Edition provides detailed, practical information on recognizing and treating heart rhythm disturbances for clinicians with any level of expertise. The author team, led by renowned authority in cardiac electrophysiology, Dr. Brian Olshansky, guides you skillfully through the different types of arrhythmias and how they present on ECGs. You'll find specific examples of each arrhythmia, numerous algorithms to facilitate an approach to arrhythmia diagnosis and management, updates on medical therapy, and indications for implantable rhythm management devices and ablation - all in a convenient, softcover volume that's perfect for on-the-go reference.
(source: Nielsen Book Data)9780323399685 20170410
Book
xix, 293 pages : illustrations ; 25 cm
  • An Introduction to Arsenic-- Arsenic is Everywhere-- Some Non-Human Arsenic Eaters-- The Toxicity of Arsenic-- Medicinal Arsenic-- Arsenic and Alternative Medicines-- Arsenic in Food-- Arsenic and the Evening Meal.
  • (source: Nielsen Book Data)9781782623144 20170213
Arsenic is a naturally occurring element and, as such, it is present in the environment and in our food and drink. It can even be involved in supporting life processes. However, due to its toxicity, there is concern about its presence in our diet. This book examines the real risks and impacts of arsenic in our lives. Looking at arsenic and its compounds, this book explores the presence of arsenic in food and water, the need to clarify its toxicity, and current scientific and public misconceptions about arsenic. It also looks at the use of arsenic in medicine, from cancer treatments to alternative therapies such as homeopathy. Following on from "Is Arsenic an Aphrodisiac?: The Sociochemistry of an Element", this book continues the authors work in addressing the issues surrounding arsenic. It is a fascinating read for general readers as it unveils the reality of our exposure to arsenic in our daily lives.
(source: Nielsen Book Data)9781782623144 20170213
Science Library (Li and Ma)
Book
1 online resource.
  • 1. Network of Cells and Mediators of Innate and Adaptive Cutaneous Immunity: Challenges for an Arthropod Vector 2. Vector Arthropods and Host Pain and Itch Responses 3. Arthropod Modulation of Wound Healing 4. Salivary Kratagonists: Scavengers of Host Physiological Effectors During Blood Feeding 5. Basic and Translational Research on Sand Fly Saliva: Pharmacology, Biomarkers, and Vaccines 6. Unique Features of Vector-Transmitted Leishmaniasis and Their Relevance to Disease Transmission and Control 7. Early Immunological Responses Upon Tsetse Fly-Mediated Trypanosome Inoculation 8. Mosquito Modulation of Arbovirus-Host Interactions 9. Tick Saliva: A Modulator of Host Defenses 10. Tick Saliva and Microbial Effector Molecules: Two Sides of the Same Coin 11. Tsetse Fly Saliva Proteins as Biomarkers of Vector Exposure 12. Epidemiological Applications of Assessing Mosquito Exposure in a Malaria-Endemic Area 13. Ixodes Tick Saliva: A Potent Controller at the Skin Interface of Early Borrelia burgdorferi Sensu Lato Transmission 14. Translation of Saliva Proteins Into Tools to Prevent Vector-Borne Disease Transmission 15. Considerations for the Translation of Vector Biology Research.
  • (source: Nielsen Book Data)9780128053607 20170612
Arthropod Vector: Controller of Disease Transmission, Volume 2: Vector Saliva-Host Pathogen Interactions is built on topics initially raised at a related Keystone Symposium on Arthropod Vectors. Together with the separate, related Volume 1: Controller of Disease Transmission, this work presents a logical sequence of topic development that leads to regulatory considerations for advancing these and related concepts for developing novel control measures. The three themes of symbionts, vector immune defenses and arthropod saliva modulation of the host environment are central to the concept of determinants of vector competence that involves all aspects of vector-borne pathogen development within the arthropod that culminates in the successful transmission to the vertebrate host. These three areas are characterized at the present time by rapid achievement of significant, incremental insights, which advances our understanding for a wide variety of arthropod vector species, and this work is the first to extensively integrate these themes.
(source: Nielsen Book Data)9780128053607 20170612
Book
1 online resource.
  • 1. Network of Cells and Mediators of Innate and Adaptive Cutaneous Immunity: Challenges for an Arthropod Vector 2. Vector Arthropods and Host Pain and Itch Responses 3. Arthropod Modulation of Wound Healing 4. Salivary Kratagonists: Scavengers of Host Physiological Effectors During Blood Feeding 5. Basic and Translational Research on Sand Fly Saliva: Pharmacology, Biomarkers, and Vaccines 6. Unique Features of Vector-Transmitted Leishmaniasis and Their Relevance to Disease Transmission and Control 7. Early Immunological Responses Upon Tsetse Fly-Mediated Trypanosome Inoculation 8. Mosquito Modulation of Arbovirus-Host Interactions 9. Tick Saliva: A Modulator of Host Defenses 10. Tick Saliva and Microbial Effector Molecules: Two Sides of the Same Coin 11. Tsetse Fly Saliva Proteins as Biomarkers of Vector Exposure 12. Epidemiological Applications of Assessing Mosquito Exposure in a Malaria-Endemic Area 13. Ixodes Tick Saliva: A Potent Controller at the Skin Interface of Early Borrelia burgdorferi Sensu Lato Transmission 14. Translation of Saliva Proteins Into Tools to Prevent Vector-Borne Disease Transmission 15. Considerations for the Translation of Vector Biology Research.
  • (source: Nielsen Book Data)9780128053607 20170612
Arthropod Vector: Controller of Disease Transmission, Volume 2: Vector Saliva-Host Pathogen Interactions is built on topics initially raised at a related Keystone Symposium on Arthropod Vectors. Together with the separate, related Volume 1: Controller of Disease Transmission, this work presents a logical sequence of topic development that leads to regulatory considerations for advancing these and related concepts for developing novel control measures. The three themes of symbionts, vector immune defenses and arthropod saliva modulation of the host environment are central to the concept of determinants of vector competence that involves all aspects of vector-borne pathogen development within the arthropod that culminates in the successful transmission to the vertebrate host. These three areas are characterized at the present time by rapid achievement of significant, incremental insights, which advances our understanding for a wide variety of arthropod vector species, and this work is the first to extensively integrate these themes.
(source: Nielsen Book Data)9780128053607 20170612
Book
1 online resource.
  • 1. Introduction (Kevin Browne, Anthony Beech and Leam Craig). Part I: CRIMINAL JUSTICE ASSESSMENTS. 2. Risk Assessment and Formulation (Peter Sturmey). 3. Violent Offenders and Murderers (Kevin Howells and Kerry Sheldon). 4. Sexual Offenders (Anthony Beech & Leam A. Craig and Franca Cortoni). 5. Firesetters (Lyndsey Gozna). 6. Parole Assessments (Louise Bowers). PART II: OFFENDERS WITH MENTAL DISORDERS. 7. Assessing Risk of Violence in Mentally Disordered Offenders (James Mcguire). 8. Major Mental Illness and Detention (Brian Thomas Peter and Tanya Garret). 9. Assessing Mental Capacity in Learning Disabled Offenders (Leam A Craig and Roger Hutchinson). 10. Offenders with Personality Disorders (Caroline Logan). 11. Offenders with Mental Disorders and Substance Abuse (Mike Wheatley). PART III: FAMILY VIOLENCE. 12. Community Approaches to Preventing Family Violence (Kevin Browne). 13. Parental Assessments in Childcare Proceedings (Eugene Ostapiuk). 14. Perpetrators of Domestic Violence (Louise Dixon and Kevin Browne). PART IV: POLICY AND PRACTICE. 15. Behavioural Investigative Advisors and Police Work (Laurence Alison and Alisdair Goodwill). 16. Assessment of Hostage Situations and their Perpetrators (Carol Ireland). 17. The Child Victim as a Witness (Kevin Browne). 18. Working with Young Offenders (Clive Hollin). 19. Ethics of Risk Assessment (Tony Ward). 20. Conclusions and future directions (Kevin Browne, Anthony Beech and Leam Craig).
  • (source: Nielsen Book Data)9780470019016 20170403
Assessments in Forensic Practice: A Handbook provides practical guidance in the assessment of the most frequently encountered offender subgroups found within the criminal justice system. Topics include: criminal justice assessments offenders with mental disorders family violence policy and practice.
(source: Nielsen Book Data)9780470019016 20170403
Book
1 online resource (631 p.) n: ill.
  • 1 Introduction and Historical Aspects 2 Physiologic Principles 3 Control of Ventilation 4 Ethical Issues in Assisted Ventilation of the Neonate 5 Evidence-Based Respiratory Care 6 Quality and Safety in Respiratory Care 7 Medical and Legal Aspects of Respiratory Care 8 Physical Examination 9 Imaging: Radiography, Lung Ultrasound, and Other Imaging Modalities 10 Blood Gases: Technical Aspects and Interpretation 11 Non-invasive Monitoring of Gas Exchange 12 Pulmonary Function and Graphics 13 Airway Evaluation: Bronchoscopy, Laryngoscopy, and Tracheal Aspirates 14 Cardiovascular Assessment 15 Overview of Assisted Ventilation 16 Oxygen Therapy 17 Non-invasive Respiratory Support 18 Basic Modes of Synchronized Ventilation 19 Principles of Lung-Protective Ventilation 20 Tidal Volume-Targeted Ventilation 21 Special Techniques of Respiratory Support 22 High-Frequency Ventilation 23 Mechanical Ventilation: Disease-Specific Strategies 24 Weaning from Mechanical Ventilation 25 Description of Available Devices 26 Delivery Room Stabilization, and Respiratory Support 27 Respiratory Care of the Newborn 28 Nursing Care 29 Nutritional Support 30 Complications of Respiratory Support 31 Pharmacologic Therapies I: Surfactant Therapy 32 Pharmacologic Therapies II: Inhaled Nitric Oxide 33 Pharmacologic Therapies III: Cardiovascular Therapy and Persistent Pulmonary Hypertension of the Newborn 34 Pharmacologic Therapies IV: Other Medications 35 Management of the Infant with Bronchopulmonary Dysplasia 36 Medical and Surgical Interventions for Respiratory Distress and Airway Management 37 Intraoperative Management of the Neonate 38 Neonatal Respiratory Care in Resource-Limited Countries 39 Transport of the Ventilated Infant 40 Extracorporeal Membrane Oxygenation 41 Discharge and Transition to Home Care 42 Neurologic Effects of Respiratory Support 43 Pulmonary and Neurodevelopmental Outcomes Following Ventilation.
  • (source: Nielsen Book Data)9780323390064 20161114
Extensively updated and featuring a new editorial team, the 6th Edition of Assisted Ventilation of the Neonate, by Drs. Jay P. Goldsmith, Edward Karotkin, Gautham Suresh, and Martin Keszler, continues to be a must-have reference for the entire NICU. Still the only fully comprehensive guide in this fast-changing area, it provides expert guidance on contemporary management of neonatal respiratory diseases, with an emphasis on evidence-based pharmacologic and technologic advances to improve outcomes and quality of life in newborns. A new full-color design and chapter layout combine for quick and easy reference.
(source: Nielsen Book Data)9780323390064 20161114
Book
1 online resource : illustrations (black and white)
A world awash in little understood chemicals tragically harms adults and children alike. Laws keep health agencies in the dark about toxicants, slow, well motivated research hampers protections, and strenuous vested opposition exacerbates the harm. How science is used in the tort law can facilitate or frustrate redress of harm. This work recommends better approaches.
Book
x, 300 pages, 16 unnumbered pages of plates : illustration (some color) ; 24 cm
  • Adolecent and Adult Outcomes of Childhood Attention Deficit Hyperactivity Disorder : The Montreal Study / Mariya V. Cherkasova, Gabrielle Weiss, and Lily Hechtman
  • Long-term Outcomes of Childhood Attention Deficit Hyperactivity Disorder : The New York Study / Sylvaine Houssais, Lily Hechtman, and Rachel G. Klein
  • The Milwaukee Longitudinal Study of Hyperactive (ADHD) Children / Russell A. Barkley and Mariellen Fischer
  • The Pittsburgh ADHD Longitudinal Study (PALS) / Brooke S.G. Molina, Margaret H. Sibley, Sarah L. Pedersen, and William E. Pelham, Jr.
  • Young Adult Outcome of Attention Deficit Hyperactivity Disorder : Results from the Longitudinal Massachusetts General Hospital Sample of Pediatrically and Psychiatrically Referred Youth with and without ADHD of Both Sexes / Mai Uchida and Joseph Biederman
  • The Berkeley Girls with ADHD Longitudinal Study / Elizabeth B. Owens, Christine A. Zalecki, and Stephen P. Hinshaw
  • The Multimodal Treatment of Children with ADHD (MTA) Follow-up Study : Outcomes and Their Predictors / Arunima Roy and Lily Hechtman
  • Influence of Treatment on Long-term Outcome / Lily Hechtman
  • Summary / Lily Hechtman.
The book provides a comprehensive summary of the best known and most highly respected well-controlled long-term prospective follow-up studies in ADHD. These studies followed children with ADHD and matched controls into young adulthood (mean age 20-25 years) and middle-age (mean age 41 years). They explore a wide variety of outcome areas, e.g. education, occupation, emotional and psychiatric functioning, substance use and abuse, sexual behavior, as well as legal problems. One chapter focuses particularly on the outcome of girls with ADHD. Outcome areas explored are thus comprehensive and clinically very relevant. The book also explores the possible predictors of adult outcome. A whole chapter is devoted to treatment (medication and psychosocial) as a predictor of outcome. In addition to treatment, predictors explored include characteristics of the child (e.g., IQ, severity of initial ADHD symptoms, initial comorbidity characteristics of the family, e.g., socioeconomic status, single parenthood, parental pathology, and family functioning. In a summary chapter, the impact and importance of these various predictors in different outcome areas, e.g. education, occupation, emotional/social functioning, antisocial behavior, substance use and abuse and risky sexual and driving behaviors are explored. In summary, the book provides a comprehensive view of the prognosis, e.g., long-term outcome of ADHD and key factors which can influence this outcome. Professionals and the general public will thus get a clear view of what can happen to children with ADHD as they proceed through adolescence and adulthood and address important prognostic and predictive factors in their treatment approaches to ensure better long-term outcome in patients with ADHD.
(source: Nielsen Book Data)9780190213589 20161124
SAL1&2 (on-campus shelving)
Book
xiii, 254 pages : illustrations ; 22 cm
  • Sports concussion myths and fears
  • Athletes, concussions, and the playing field
  • You think you might have a concussion, how do you know?
  • Life after a diagnosis of concussion
  • Post-concussion syndromes and second-impact syndrome
  • Concussion, sports, depression, and suicide?
  • How athletes can help themselves
  • Advice for parents and coaches
  • Changing our game, on and off the field
  • Controlling the messaging of concussion.
The word concussion used to be unheard of in youth sports a decade ago. The brain injury was indeed occurring, but coaches and parents were encouraging their youth athletes to "shake it off" after "getting their bell rung". Science and increased awareness about concussion are transforming the way youth parents, coaches, and players pursue athletics. Fear of incurring concussions, as well as incorrect information, is leading some parents to keep their children out of contact sports, such as football and soccer, where concussion is more prevalent. Back in the Game: Why Concussion Doesn't Have to End Your Athletic Career does not dwell on perpetuating fears, but rather, provides the most up-to-date understanding of the condition. This text includes a real-world discussion of what science and medicine knows, what parents and coaches need to understand about concussions, evaluation and treatment, and possible post-concussive issues, like depression. At the heart of this book, the authors delve into these issues, explaining them in a clear and understandable way. The expertise and experiences of noted sports neurologist Jeffrey Kutcher, MD, along with reporting and interviews by award-winning sports journalist Joanne C. Gerstner, makes this book a timely, relevant, and real discussion about concussions in youth sports. Athletes and professional coaches who have participated in the formation of this book include two-time Olympic gold medalist soccer player Kate Markgraf, former NHL/Team Canada head coach Andy Murray, champion X-Games snowboarder Ellery Hollingsworth, along with an array of youth parents, coaches, and athletes from across the country.
(source: Nielsen Book Data)9780190226602 20161108
SAL1&2 (on-campus shelving)